uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
62.02
+0.46 (0.75%)
At close: Oct 13, 2025, 4:00 PM EDT
61.80
-0.22 (-0.35%)
After-hours: Oct 13, 2025, 7:58 PM EDT
uniQure Revenue
uniQure had revenue of $5.26M in the quarter ending June 30, 2025, a decrease of -52.71%. This brings the company's revenue in the last twelve months to $14.34M, down -48.25% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$14.34M
Revenue Growth
-48.25%
P/S Ratio
223.51
Revenue / Employee
$68,598
Employees
209
Market Cap
3.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
QURE News
- 5 days ago - uniQure: Further Upside Likely As The Opportunity Becomes Better Understood - Seeking Alpha
- 14 days ago - uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - GlobeNewsWire
- 17 days ago - uniQure Announces Pricing of Upsized $300 Million Public Offering - GlobeNewsWire
- 18 days ago - UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street - Benzinga
- 18 days ago - uniQure Stock Jumps On Positive News, But Risks Remain - Benzinga
- 18 days ago - UniQure: How QURE Stock Rises 10x To $500? - Forbes
- 19 days ago - Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it - Market Watch
- 19 days ago - uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond - Seeking Alpha